Earnings

ALX Oncology Holdings Q2 Adj. EPS $(0.11) Beats $(0.14) Estimate

Aug 6, 2026 · 08:39 AM ET· updated 2h ago

ALX Oncology Holdings (NASDAQ:ALXO) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.14) by 21.43 percent. This is a 75 percent increase over losses of $(0.44) per share

Why It Matters

ALX Oncology lost less money per share than experts expected, and their losses shrank a lot compared to last year. When a company is improving its losses like this, it shows the business is moving in a better direction.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

ALXO1.99

+0.07 (+3.39%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.